Release
📈 Stocks
Jazz Pharmaceuticals Reports 40% Three-Year Survival Rate for Ziihera Combo
(10 minutes ago)
Jazz Pharmaceuticals and partner BeiGene report a 27-month median overall survival for Ziihera-based regimens in HER2+ gastroesophageal cancer, bolstering the case for…